Beijing Minhai Biotechnology Co., Ltd
Quick facts
Phase 3 pipeline
- Act-HIB® · Immunology / Infectious Disease
Act-HIB is a conjugate vaccine that stimulates immune response against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier. - Hib Vaccine Group · Immunology
Hib vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) bacteria, preventing infection. - MCV-AC Vaccine Group · Immunology / Infectious Disease
MCV-AC is a meningococcal conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis to prevent meningococcal disease. - MCV-ACYW135 Vaccine Group · Immunology
MCV-ACYW135 is a meningococcal conjugate vaccine that stimulates immune response against serogroups A, C, Y, and W-135 of Neisseria meningitidis. - Minhai-HIB · Immunology / Infectious Disease
Minhai-HIB is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates immune responses against the polysaccharide capsule of H. influenzae type b bacteria. - MPV-A Vaccine Group · Immunology
MPV-A is a multi-pathogen vaccine designed to provide immunological protection against multiple viral pathogens through stimulation of adaptive immune responses. - MPV-ACYW135 Vaccine Group · Immunology
MPV-ACYW135 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against serogroups A, C, Y, and W-135 of Neisseria meningitidis. - pneumococcal disease prevention
- sIPV+bOPV · Infectious Diseases
This vaccine combines inactivated poliovirus (sIPV) and oral poliovirus vaccine (bOPV) to provide immunity against poliomyelitis. - wIPV · Infectious Diseases
WIPV is a small molecule targeting the SARS-CoV-2 main protease. - wIPV+bOPV · Infectious Disease
WIPV+bOPV is a vaccine that targets the SARS-CoV-2 virus.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: